ERBB2 and cancer: In conclusion, we show PHLDA2 regulation by EGFR/ErbB2 signaling, demonstrate a correlation between PHLDA2 expression, AKT pathway activation and EGFR mutational status and show that PHLDA2 has key negative feedback inhibitory functions in EGFR/ErbB2-driven cancer cells.